Tình trạng pháp lý: Hợp chất đang trong danh mục nghiên cứu, đang phát triển, chưa được phê duyệt
Tên IUPAC: N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide;methylsulfinylmethane
Số EC: 629-898-8
Khối lượng phân tử: 693.5
Công thức hoá học: C₂₈H₂₉FIN₅O₅S
Số CAS: 1187431-43-1
Ứng dụng: Nguyên liệu API ung thư dùng phối hợp với thuốc ức chế MEK (ung thư đột biến BRAF, u thần kinh đệm)
Dạng bào chế: Dạng solvat DMSO (dạng đa hình)
Xuất xứ: Châu Âu (nhà sản xuất API tại EU)
Status: Pipeline
Development phase: Under development
Therapeutic cat.: Oncology
Polymorphic form: DMSO solvate
OEB No.: 5
Samples: Q4 2024

Thông tin khác

Mô tả thêm:

Established in 1935 and based in the Greater Poland Voivodeship, Polpharma is a manufacturer and service provider of active pharmaceutical ingredients spanning prophylactic biological products, central nervous system drugs, cardiovascular system drugs and related APIs, offering CDMO contract manufacturing to markets across North America, Latin America, Western and Eastern Europe, Australasia, Asia, the Middle East and Africa. Drawing on 75 years of experience in the API business, Polpharma API covers the full value chain from R&D through production and supply chain management to project management, operating from a European base with R&D and two manufacturing plants, and specializes in high-potency APIs (OEB 5&6), high-potency ADC payloads, advanced linker technologies, customizable ADC development solutions, cryogenic reactions and oligonucleotides. The company is recognized for international certification, an experienced R&D team, strong reputation, high-quality service and a genuinely global market presence.